The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C).Aurora kinases regulate a variety of cell cycle-related processes and are necessary for the assembly and operation of the bipolar spindle during the mitotic and meiotic phases.
While Aurora-A, Aurora-B, and Aurora-C have very similar subcellular localizations and functions during mitosis, they also share a highly conserved kinase domain. While Aurora-B and Aurora-C are necessary for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis, Aurora-A primarily regulates centrosome maturation and bipolar spindle assembly. All Aurora kinase members play oncogenic roles related to their mitotic activity and support the survival and growth of cancer cells in human tumors. Researchers studying cancer have become interested in inhibitors that target Aurora kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0343 | Alisertib (MLN8237, MLN-8237) | 1028486-01-2 | Alisertib (also named as MLN8237, MLN-8237) is a novel potent, selective, orally bioavailableAurora A kinase (AAK) inhibitor with potential antitumor activity. |
|
V0365 | AMG-900 | 945595-80-2 | AMG 900 (AMG-900), a phtha-lazinamine compound,is a novel and ATP-competitive pan-Aurora (A/B/C) kinase inhibitor with potential antitumor activity. |
|
V0345 | Barasertib ( INH-34; AZD-1152-HQPA) | 722544-51-6 | Barasertib (INH34; AZD1152 or AZD1152-HQPA) is a novel, potent, highly selective, orally bioavailable small-molecule Aurora B inhibitor with potential antitumor activity. |
|
V0350 | BI-847325 | 1207293-36-4 | BI-847325 (BI847325) is a novel, potent, orally bioavailable, and selective dual inhibitor of MEK (mitogen-activated protein kinase kinase) and Aurora kinase with potential antitumor activity. |
|
V0359 | CCT129202 | 942947-93-5 | CCT129202 (CCT-129202), animidazopyridine compound,is a potent andATP-competitive pan-Aurora inhibitor with potential antitumor activity. |
|
V0356 | CCT137690 | 1095382-05-0 | CCT137690 is a novel, potent, highly selective andorally bioavailable inhibitor of Aurora kinase A/B/C with potential antitumor activity. |
|
V0364 | CYC116 | 693228-63-6 | CYC116 is a novel, potent, orally bioavailable inhibitor of Aurora A/B/C kinases with potential antitumor activity. |
|
V0348 | Danusertib (PHA739358) | 827318-97-8 | Danusertib (formerly PHA-739358), apyrrolo-pyrazole compound,is a potent Aurora kinase inhibitor of Aurora A/B/C with potential antitumor activity. |
|
V0363 | ENMD-2076 | 934353-76-1 | ENMD-2076 (ENMD2076) is a novel,potent andorally bioactive inhibitor of multikinase including Aurora A and Flt3 with potential antitumor activity. |
|
V0355 | GSK1070916 (NMI900 or GSK1070916 A) | 942918-07-2 | GSK1070916 (also known as NMI-900 or GSK-1070916A)is a novel, potent, reversible and ATP-competitive inhibitor of Aurora B/C with potential antitumor activity. |
|
V0361 | Hesperadin | 422513-13-1 | Hesperadin is a novel, potent and ATP-competitive inhibitor of human aurora B kinase with potential antitumor activity. |
|
V0354 | JNJ-7706621 | 443797-96-4 | JNJ-7706621 (JNJ7706621) is novel and potent pan-CDK (cyclin-dependent kinases) inhibitor and also an Aurora-A and Aurora-B inhibitor with potential antitumor activity. |
|
V0353 | KW-2449 | 1000669-72-6 | KW-2449 (KW2449) is a novel, potent, multiple-kinase (e. |
|
V0357 | MK-5108 (VX689) | 1010085-13-8 | MK-5108 (also known as VX-689)is a novel, specific and ATP-competitive inhibitor of Aurora A kinase with potential anticancer activity. |
|
V0352 | MK-8745 | 885325-71-3 | MK-8745 is a novel, potent, specific and selective Aurora A inhibitor with potential antitumor activity. |
|
V0347 | MLN8054 | 869363-13-3 | MLN-8054 (MLN8054), abenzazepine-based compound, is a selective, and ATP-competitive inhibitor of Aurora A kinase (AAK) with potential antitumor activity. |
|
V0366 | PF-03814735 | 942487-16-3 | PF-03814735 (PF03814735) is a reversible,orally bioavailable, and ATP-competitive inhibitor of Aurora A/B kinases with potential antitumor activity. |
|
V0360 | PHA-680632 | 398493-79-3 | PHA-680632 (PHA680632) is a novel and potent pan-aurora kinase inhibitor with potential antitumor activity. |
|
V3115 | SNS-314 | 1057249-41-8 | SNS-314 (SNS314) is a novel, potent and selective, synthetic small molecule inhibitor of Aurora A/B/C with anticancer activity. |
|
V0367 | SNS-314 Mesylate | 1146618-41-8 | SNS-314 mesylate, the mesylate salt ofSNS314, is a pan-Aurora kinase inhibitor with potential antineoplastic activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
